Skip to content
DataLookout
Menu

NCT07903701

A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic Stroke

StatusNot Yet Recruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Secondary endpoints: 2 to 8
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Proportion of patients achieving a modified Rankin Scale (mRS) score of 0-1 at Day 90
Timeframe: Day 90

Secondary (8)

mRS distribution at Day 30 and 90;
Proportions of symptomatic intracranial hemorrhage within 36 h, intracranial hemorrhage, and major extracranial hemorrhage 90-day mortality
Number of Participants With Any Adverse Event (AE)
Number of Participants With Treatment-Related Adverse Events (TRAEs)
Number of Participants With Serious Adverse Events (SAEs)
Show 3 moreShow less
Number of Participants With Clinically Significant Abnormal Laboratory Values
Number of Participants With Clinically Significant Abnormal Vital Signs
Number of Participants With Clinically Significant Abnormal Physical Examination Findings

Arms and interventions

SIM0811 2 Dose Level A (Phase II)Experimental

Participants receive SIM0811 Dose Level A.

SIM0811 Dose Level B (Phase II)Experimental

Participants receive SIM0811 Dose Level B.

SIM0811Dose Level C (Phase II)Experimental

Participants receive SIM0811 Dose Level C.

Placebo(Phase II)Placebo comparator

Participants receive SIM0811 placebo.

SIM0811(Phase III)Experimental

Participants receive the selected target dose of SIM0811.

Placebo (Phase III)Placebo comparator

Participants receive SIM0811 placebo.

Drugs: SIM0811 Dose Level A (Phase II), SIM0811 Dose Level B (Phase II), SIM0811 Dose Level C (Phase II), Placebo(Phase II), SIM0811(Phase III), Placebo(Phase III)